Keywords: نیلوتینیب; Chronic myeloid leukemia; Suboptimal response; Nilotinib; Imatinib;
مقالات ISI نیلوتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: نیلوتینیب; Nilotinib; Pigmentation; CREB; PKA;
Keywords: نیلوتینیب; Nilotinib; Lithium; Cell death; Autophagy; Bcr-Abl; GSK-3β; Clonogenicity; Leukemia cells;
Keywords: نیلوتینیب; Dasatinib; Deep molecular response; Imatinib; Minimal residual disease; Nilotinib;
Keywords: نیلوتینیب; Chronic graft-versus-host disease; Nilotinib; Clinical trial;
Keywords: نیلوتینیب; Parkinson's Disease; Repurposing; Glucagon-like peptide-1 (GLP-1) receptor agonists; Nilotinib;
Keywords: نیلوتینیب; Allogeneic stem cell transplantation; BCR-ABL; chronic myeloid leukaemia; dasatinib; imatinib; nilotinib; Philadelphia chromosome; ponatinib; quantitative RT-PCR; tyrosine kinase inhibitors;
Keywords: نیلوتینیب; Cisplatin; Nilotinib; Hepato-Nephrotoxicity; Oxidative stress; Apoptosis;
Keywords: نیلوتینیب; Nilotinib hydrochloride (PubChem CID: 16006490); Nilotinib; Solubility; Spray drying; Dissolution; Formulation improvement;
Keywords: نیلوتینیب; Acute lymphoblastic leukemia; ALL; Allogeneic; Cytogenetics; Dasatinib; Imatinib; Minimal residual disease; MRD; Nilotinib; Philadelphia chromosome positive; Ph+; Ponatinib; Stem cell transplant; TKI; Tyrosine kinase inhibitor;
Keywords: نیلوتینیب; przewlekła białaczka szpikowa; oporność na imatynib; dazatynib; nilotynibChronic myeloid leukemia; Imatinib resistance; Nilotinib; Dasatinib
Keywords: نیلوتینیب; Chronic myeloid leukemia; Nilotinib; Cardiovascular risk; Prognosis;
Keywords: نیلوتینیب; Bosutinib; Dasatinib; Nilotinib; Ponatinib; Radotinib
Keywords: نیلوتینیب; Endothelial activation; Nilotinib; Platelet activation; Bcr-Abl tyrosine kinase; Thrombosis; P-selectin
Keywords: نیلوتینیب; CML; Dasatinib; Liver dysfunction; Nilotinib; Renal dysfunction;
Keywords: نیلوتینیب; Cure; Dasatinib; Imatinib; Molecular remission; Nilotinib;
Keywords: نیلوتینیب; Adherence; Dasatinib; Frequency of response assessments; Imatinib; Nilotinib;
Keywords: نیلوتینیب; Tyrosine kinase inhibitors; Nilotinib; Imatinib; Quantum mechanics; Binding energies; Error assessment
Keywords: نیلوتینیب; Heat pain; Cold pain; c-Kit; Imatinib; Nilotinib; Tactile acuity; Chronic myeloid leukemia; Analgesia; Quantitative sensory testing;
Keywords: نیلوتینیب; Chronic myeloid leukemia; Tyrosine kinase inhibitors; Imatinib; Dasatinib; Nilotinib; Bosutinib; Ponatinib;
Keywords: نیلوتینیب; chronic myeloid leukemia; cost-utility analysis; dasatinib; imatinib; leukemia; nilotinib; Thailand;
Keywords: نیلوتینیب; Imatinib; Nilotinib; Chronic myeloid leukemia; Pregnancy;
Keywords: نیلوتینیب; Bcr-Abl; Tyrosine kinase; Leukemia cell; Anticancer; Nilotinib;
Keywords: نیلوتینیب; Chronic myeloid leukemia; Imatinib; Nilotinib; Dasatinib; Drug resistance; Adverse drug event;
Keywords: نیلوتینیب; chronic myeloid leukemia; complete cytogenetic response; dasatinib; health technology assessment; HTA; imatinib; intermediate outcomes; major molecular response; nilotinib; surrogate end points; systematic review; technology appraisal;
Keywords: نیلوتینیب; Dasatinib; Imatinib; Nilotinib; Optic neuropathy; Chronic myeloid leukemia; Visual campimetry/perimetry
Efficacy and safety of nilotinib 300â¯mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
Keywords: نیلوتینیب; Nilotinib; Tyrosine kinase inhibitor; Chronic myeloid leukemia;
Blockage of endoplasmic reticulum stress attenuates nilotinib-induced cardiotoxicity by inhibition of the Akt-GSK3β-Nox4 signaling
Keywords: نیلوتینیب; Nilotinib; ER stress; Akt; GSK3β; Nox4; Apoptosis;
A case report of multiple system atrophy treated with an Abelson tyrosine kinase inhibitor
Keywords: نیلوتینیب; Multiple system atrophy; Nilotinib; α-Synucleinopathy; Abelson tyrosine kinase inhibitor;
Clinical TrialImatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG)
Keywords: نیلوتینیب; Desmoid tumour; Imatinib; Nilotinib; Positron emission tomography; Progression arrest;
Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels
Keywords: نیلوتینیب; ABC transporters; Tyrosine kinase inhibitors; Drug resistance; Transporter expression level; Inhibitor efficiency; IM; imatinib; NIL; nilotinib; CsA; cyclosporin A; ZSQ; zosuquidar; DRN; daunorubicin; ECACC; European Collection of Authenticated Cell Cultu
A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma
Keywords: نیلوتینیب; UPLC-MS/MS; Imatinib; Dasatinib; Nilotinib; Polymorphism;
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
Keywords: نیلوتینیب; Acalabrutinib; Alectinib; Brigatinib; Ceritinib; Crizotinib; Dabrafenib; Dasatinib; Erlotinib; Gefitinib; Ibrutinib; Imatinib; Lorlatinib; Nilotinib; Osimertinib; Rociletinib; Trametinib; Vemurafenib;
Optimizing the Use of TKIs in the Management of Chronic Myelogenous Leukemia
Keywords: نیلوتینیب; Bosutinib; Chronic myelogenous leukemia; Dasatinib; Imatinib; Nilotinib; Tyrosine kinase inhibitor
Beneficial effects of nilotinib, tyrosine kinase inhibitor on cyclosporine-A induced renal damage in rats
Keywords: نیلوتینیب; Cyclosporine A; Nephropathy; Nilotinib; Free radical; Inflammation; Apoptosis
Binding mechanism of the tyrosine-kinase inhibitor nilotinib to human serum albumin determined by 1H STD NMR, 19F NMR, and molecular modeling
Keywords: نیلوتینیب; Human serum albumin; Nilotinib; Binding; NMR spectroscopy; Fluorescence spectroscopy; Molecular docking
Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods
Keywords: نیلوتینیب; Imatinib; Nilotinib; Dasatinib; HPLC; LC-MS/MS;
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study
Keywords: نیلوتینیب; Chronic myeloid leukemia; Clinical trials; Imatinib-related chronic adverse events; Nilotinib; Switch;
The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal-Implications for targeted therapies
Keywords: نیلوتینیب; Prostate cancer; Translational therapeutics; Nilotinib; ERK; Drug resistance;
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
Keywords: نیلوتینیب; BCR-ABL1 mutations; Dasatinib; Imatinib; Nilotinib; Tyrosine kinase inhibitor;
Response and Adverse Effects of Nilotinib in Imatinib-resistant Chronic Myeloid Leukemia Patients: Data From a Developing Country
Keywords: نیلوتینیب; chronic myeloid leukemia; cytogenetic response; hematologic response; imatinib; nilotinib; overall survival;
Matrix effects in nilotinib formulations with pH-responsive polymer produced by carbon dioxide-mediated precipitation
Keywords: نیلوتینیب; Nilotinib (PubChem CID: 644241); HPMC (PubChem CID: 57503849); Phthalic acid (PubChem CID: 1017); Amorphous; Dissolution; Nilotinib; Protein kinase inhibitor; pH sensitive polymer; UV imaging;
Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response
Keywords: نیلوتینیب; CML BCR-ABL; Molecular diagnostics; Minimal residual disease; Nilotinib
Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis
Keywords: نیلوتینیب; Chart review; Chronic myelogenous leukemia; Dasatinib; Nilotinib; Treatment response
Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC–MS/MS: Application to a pharmacokinetic study
Keywords: نیلوتینیب; Ruxolitinib; Nilotinib; Plasma; LC–MS/MS
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis
Keywords: نیلوتینیب; Chronic myeloid leukemia; Comparative effectiveness; Network meta-analysis; Major molecular response; Nilotinib; Dasatinib; Imatinib;
A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Keywords: نیلوتینیب; Dasatinib; Imatinib; Nilotinib; Outcomes; Response;
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
Keywords: نیلوتینیب; Gastrointestinal stromal tumour; GIST; Sorafenib; Nilotinib; Sunitinib; Imatinib; Tyrosine kinase inhibitor; Relapse; Salvage; Progression
Evaluation of the pharmacokinetics and cardiotoxicity of doxorubicin in rat receiving nilotinib
Keywords: نیلوتینیب; Doxorubicin; Nilotinib; P-Glycoprotein; Cardiotoxicity; Pharmacokinetic; Disposition
A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia
Keywords: نیلوتینیب; Chronic myeloid leukaemia; Tyrosine kinase inhibitors; Dasatinib; Nilotinib